Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines

Adam Giermasz, Julie A. Urban, Yutaro Nakamura, Payal Watchmaker, Rachel L. Cumberland, William Gooding, Pawel Kalinski

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

While multiple pathways of dendritic cell (DC) maturation result in transient production of IL-12, fully mature DCs show reduced ability to produce IL-12p70 upon a subsequent interaction with Ag-specific T cells, limiting their in vivo performance as vaccines. Such "DC exhaustion" can be prevented by the presence of IFNγ during the maturation of human DCs (type-1-polarization), resulting in improved induction of tumor-specific Th1 and CTL responses in vitro. Here, we show that type-1 polarization of mouse DCs strongly enhances their ability to induce CTL responses against a model tumor antigen, OVA, in vivo, promoting the induction of protective immunity against OVA-expressing EG7 lymphoma. Interestingly, in contrast to the human system, the induction of mouse DC1s requires the participation of IL-4, a nominal Th2-inducing cytokine. The current data help to explain the previously reported Th1-driving and anti-tumor activities of IL-4, and demonstrate that type-1 polarization increases in vivo activity of DC-based vaccines.

Original languageEnglish (US)
Pages (from-to)1329-1336
Number of pages8
JournalCancer Immunology, Immunotherapy
Volume58
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Cancer Vaccines
Interleukin-12
Dendritic Cells
Interleukin-4
Vaccines
Neoplasm Antigens
Immunity
Lymphoma
Neoplasms
Cytokines
T-Lymphocytes

Keywords

  • Dendritic cells
  • IL-12
  • IL-4
  • Lymphoma
  • Mouse
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Oncology

Cite this

Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. / Giermasz, Adam; Urban, Julie A.; Nakamura, Yutaro; Watchmaker, Payal; Cumberland, Rachel L.; Gooding, William; Kalinski, Pawel.

In: Cancer Immunology, Immunotherapy, Vol. 58, No. 8, 08.2009, p. 1329-1336.

Research output: Contribution to journalArticle

Giermasz, Adam ; Urban, Julie A. ; Nakamura, Yutaro ; Watchmaker, Payal ; Cumberland, Rachel L. ; Gooding, William ; Kalinski, Pawel. / Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. In: Cancer Immunology, Immunotherapy. 2009 ; Vol. 58, No. 8. pp. 1329-1336.
@article{1b55fda2a8d54073a7f01f18ea67a98e,
title = "Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines",
abstract = "While multiple pathways of dendritic cell (DC) maturation result in transient production of IL-12, fully mature DCs show reduced ability to produce IL-12p70 upon a subsequent interaction with Ag-specific T cells, limiting their in vivo performance as vaccines. Such {"}DC exhaustion{"} can be prevented by the presence of IFNγ during the maturation of human DCs (type-1-polarization), resulting in improved induction of tumor-specific Th1 and CTL responses in vitro. Here, we show that type-1 polarization of mouse DCs strongly enhances their ability to induce CTL responses against a model tumor antigen, OVA, in vivo, promoting the induction of protective immunity against OVA-expressing EG7 lymphoma. Interestingly, in contrast to the human system, the induction of mouse DC1s requires the participation of IL-4, a nominal Th2-inducing cytokine. The current data help to explain the previously reported Th1-driving and anti-tumor activities of IL-4, and demonstrate that type-1 polarization increases in vivo activity of DC-based vaccines.",
keywords = "Dendritic cells, IL-12, IL-4, Lymphoma, Mouse, Vaccines",
author = "Adam Giermasz and Urban, {Julie A.} and Yutaro Nakamura and Payal Watchmaker and Cumberland, {Rachel L.} and William Gooding and Pawel Kalinski",
year = "2009",
month = "8",
doi = "10.1007/s00262-008-0648-5",
language = "English (US)",
volume = "58",
pages = "1329--1336",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines

AU - Giermasz, Adam

AU - Urban, Julie A.

AU - Nakamura, Yutaro

AU - Watchmaker, Payal

AU - Cumberland, Rachel L.

AU - Gooding, William

AU - Kalinski, Pawel

PY - 2009/8

Y1 - 2009/8

N2 - While multiple pathways of dendritic cell (DC) maturation result in transient production of IL-12, fully mature DCs show reduced ability to produce IL-12p70 upon a subsequent interaction with Ag-specific T cells, limiting their in vivo performance as vaccines. Such "DC exhaustion" can be prevented by the presence of IFNγ during the maturation of human DCs (type-1-polarization), resulting in improved induction of tumor-specific Th1 and CTL responses in vitro. Here, we show that type-1 polarization of mouse DCs strongly enhances their ability to induce CTL responses against a model tumor antigen, OVA, in vivo, promoting the induction of protective immunity against OVA-expressing EG7 lymphoma. Interestingly, in contrast to the human system, the induction of mouse DC1s requires the participation of IL-4, a nominal Th2-inducing cytokine. The current data help to explain the previously reported Th1-driving and anti-tumor activities of IL-4, and demonstrate that type-1 polarization increases in vivo activity of DC-based vaccines.

AB - While multiple pathways of dendritic cell (DC) maturation result in transient production of IL-12, fully mature DCs show reduced ability to produce IL-12p70 upon a subsequent interaction with Ag-specific T cells, limiting their in vivo performance as vaccines. Such "DC exhaustion" can be prevented by the presence of IFNγ during the maturation of human DCs (type-1-polarization), resulting in improved induction of tumor-specific Th1 and CTL responses in vitro. Here, we show that type-1 polarization of mouse DCs strongly enhances their ability to induce CTL responses against a model tumor antigen, OVA, in vivo, promoting the induction of protective immunity against OVA-expressing EG7 lymphoma. Interestingly, in contrast to the human system, the induction of mouse DC1s requires the participation of IL-4, a nominal Th2-inducing cytokine. The current data help to explain the previously reported Th1-driving and anti-tumor activities of IL-4, and demonstrate that type-1 polarization increases in vivo activity of DC-based vaccines.

KW - Dendritic cells

KW - IL-12

KW - IL-4

KW - Lymphoma

KW - Mouse

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=67349254467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349254467&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0648-5

DO - 10.1007/s00262-008-0648-5

M3 - Article

C2 - 19156413

AN - SCOPUS:67349254467

VL - 58

SP - 1329

EP - 1336

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 8

ER -